Literature DB >> 7691957

Role of kinins in the vascular extravasation evoked by antigen and mediated by tachykinins in guinea pig trachea.

C Bertrand1, J A Nadel, I Yamawaki, P Geppetti.   

Abstract

Tachykinins released from sensory nerves mediate, at least in part, the plasma extravasation induced by allergen challenge to the airways of sensitized guinea pigs. We investigated the role of kinins in this activation of sensory nerves. We found that the increase in Evans blue dye extravasation evoked by aerosol of bradykinin (100 microM, 2 min) in the presence of phosphoramidon (2.5 mg/kg, i.v.) was abolished completely by the selective B2 bradykinin antagonist, HOE 140 (0.1 mumol/kg, i.v.), and was inhibited (60%) by the selective NK1 tachykinin receptor antagonist, CP-96,345 (2 mumol/kg, i.v.). Plasma extravasation evoked by aerosolized substance P (10 microM/kg, 2 min) in presence of phosphoramidon was abolished by CP-96,345, but was not affected by HOE 140. The extravasation of the Evans blue dye evoked by OVA (5%, 2 min) in sensitized guinea pigs was reduced by HOE 140 (45%) when the animals were perfused after 5 min and by 39% when perfusion was performed at 10 min. In the presence of phosphoramidon, the response to OVA at 10 min was reduced by 57% by HOE 140 and by 72% by CP-96,345. The combination of CP-96,345 and HOE 140 did not further increase the inhibition obtained with CP-96,345 alone. The results provide evidence that the activation of sensory nerves that contribute to Ag-evoked plasma extravasation is due to kinin release. The contribution of this cascade of events may be exaggerated in pathophysiologic conditions in which neutral endopeptidase is down-regulated.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7691957

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Inhibition of bradykinin-evoked trigeminal nerve stimulation by the non-peptide bradykinin B2 receptor antagonist WIN 64338 in vivo and in vitro.

Authors:  J M Hall; M Figini; S K Butt; P Geppetti
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

2.  Suppressive effect of distinct bradykinin B2 receptor antagonist on allergen-evoked exudation and leukocyte infiltration in sensitized rats.

Authors:  C Bandeira-Melo; A S Calheiros; P M Silva; R S Cordeiro; M M Teixeira; M A Martins
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

Review 3.  The hypersensitive esophagus: pathophysiology, evaluation, and treatment options.

Authors:  Jose M Remes-Troche
Journal:  Curr Gastroenterol Rep       Date:  2010-10

4.  Involvement of tachykinins in plasma extravasation induced by bradykinin and low pH medium in the guinea-pig conjunctiva.

Authors:  M Figini; P Javdan; F Cioncolini; P Geppetti
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

5.  An open-label trial of theophylline for functional chest pain.

Authors:  Satish S C Rao; Ranjit S Mudipalli; Victor Mujica; Craig L Utech; Xing Zhao; Jeffrey L Conklin
Journal:  Dig Dis Sci       Date:  2002-12       Impact factor: 3.199

6.  Lack of a role for bradykinin in allergen-induced airway microvascular leakage and bronchoconstriction in the guinea pig.

Authors:  T Sakamoto; P J Barnes; K F Chung
Journal:  Inflamm Res       Date:  1996-03       Impact factor: 4.575

Review 7.  Using guinea pigs in studies relevant to asthma and COPD.

Authors:  Brendan J Canning; Yangling Chou
Journal:  Pulm Pharmacol Ther       Date:  2008-02-02       Impact factor: 3.410

8.  Pharmacology of Bradykinin-Evoked Coughing in Guinea Pigs.

Authors:  Matthew M Hewitt; Gregory Adams; Stuart B Mazzone; Nanako Mori; Li Yu; Brendan J Canning
Journal:  J Pharmacol Exp Ther       Date:  2016-03-21       Impact factor: 4.030

9.  Cationic protein-induced sensory nerve activation: role of substance P in airway hyperresponsiveness and plasma protein extravasation.

Authors:  A J Coyle; F Perretti; S Manzini; C G Irvin
Journal:  J Clin Invest       Date:  1994-12       Impact factor: 14.808

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.